Novonesis reported first-half 2026 organic sales growth of 8%, lifting its full-year 2026 outlook and announcing a EUR 1 billion share buyback program as shares surged 8.5%.
The Danish biosolutions group posted H1 2026 sales of EUR 2.24 billion, up 7% from EUR 2.10 billion in the same period last year. Adjusted EBITDA reached EUR 842.2 million, with the margin expanding 30 basis points to 37.7%. Operating cash flow rose 23% to EUR 523.3 million, while adjusted earnings per share increased 9% to EUR 1.09.
The company raised its full-year 2026 organic sales growth guidance to 7-8%, excluding a 1.5 percentage point headwind from country exits. Adjusted EBITDA margin is expected at the higher end of the 37-38% range. Management also outlined modeling assumptions, including net financial expenses of EUR 80-90 million and capital expenditures of 12-14% of sales.
Regional performance showed Latin America leading with 18% growth in H1, followed by Asia Pacific at 9% and North America at 7%. Europe, the Middle East and Africa grew 4%, impacted by country exits. The Food & Health Biosolutions division grew 9% organically, while Planetary Health Biosolutions rose 7%, accelerating to 9% in the second quarter.
Novonesis also declared an interim dividend of DKK 2.35 per share, marking 26 consecutive years of payouts. The group plans to launch a EUR 1 billion share buyback program, with shares trading near a 52-week high of $450.05 after an 8.5% intraday gain to $449.50.
